Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31313781 | 0.87 | FFAR1 (0.33) | FFAR1MAPK1 | |
| SCHEMBL24002151 | 0.86 | MAPK1 (0.38) | FFAR1MAPK1P2RX7 | |
| SCHEMBL27166678 | 0.84 | FFAR1 (0.34) | FFAR1MAPK1P2RX7 | |
| SCHEMBL31115784 | 0.82 | KLKB1 (0.37) | FFAR1MAPK1 | |
| SCHEMBL31313670 | 0.80 | FFAR1 (0.32) | FFAR1MAPK1 | |
| SCHEMBL24009400 | 0.80 | MAPK1 (0.35) | FFAR1MAPK1P2RX7 | |
| SCHEMBL24010961 | 0.80 | MAPK1 (0.35) | FFAR1MAPK1P2RX7 | |
| SCHEMBL38661230 | 0.80 | MAPK1 (0.35) | FFAR1MAPK1P2RX7 | |
| SCHEMBL31115890 | 0.78 | MAPK1 (0.33) | MAPK1 | |
| SCHEMBL31115836 | 0.78 | MAPK1 (0.34) | FFAR1MAPK1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240309003-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2024-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240309003-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | FFAR1 133/4885MAPK1 1254/4885P2RX7 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.